Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
AIDS Behav ; 22(3): 1018-1024, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-28224322

RESUMO

WHO guidelines recommend immediate initiation of antiretroviral therapy (ART) for all individuals at HIV diagnosis regardless of CD4 count, but concerns remain about potential low uptake or poor adherence among healthy patients with high CD4 counts, especially in resource-limited settings. This study assessed the acceptability of earlier treatment among HIV-positive South African women, median age at enrollment 25 (IQR 22-30), in a 10 year prospective cohort study by (i) describing temporal CD4 count trends at initiation in relation to WHO guidance, (ii) virological suppression rates post-ART initiation at different CD4 count thresholds, and (iii) administration of a standardized questionnaire. 158/232 (68.1%) participants initiated ART between 2006 and 2015. Mean CD4 count at initiation was 217 cells/µl (range 135-372) before 2010, and increased to 531 cells/µl (range 272-1095) by 2015 (p < 0.001). Median viral load at ART initiation decreased over this period from 5.2 (IQR 4.6-5.6) to 4.1 (IQR 3.4-4.6) log copies/ml (p = 0.004). Virological suppression rates at 3, 6, 12 and 18 months were consistently above 85% with no statistically significant differences for participants starting ART at different CD4 count thresholds. A questionnaire assessing uptake of early ART amongst ART-naïve women, median age 28 (IQR 24-33), revealed that 40/51 (78.4%) were willing to start ART at CD4 ≥500. Of those unwilling, 6/11 (54.5%) started ART within 6 months of questionnaire administration. Temporal increases in CD4 counts, comparable virological suppression rates, and positive patient perceptions confirm high acceptability of earlier ART initiation for the majority of patients.


Assuntos
Terapia Antirretroviral de Alta Atividade/métodos , População Negra/psicologia , Infecções por HIV/tratamento farmacológico , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Prevenção Secundária , Carga Viral/efeitos dos fármacos , Adulto , População Negra/estatística & dados numéricos , Contagem de Linfócito CD4 , Estudos de Coortes , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/virologia , Humanos , Masculino , Manejo da Dor , Aceitação pelo Paciente de Cuidados de Saúde/etnologia , Estudos Prospectivos , África do Sul/epidemiologia , Inquéritos e Questionários , Adulto Jovem
2.
Antivir Ther ; 22(4): 287-293, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27835613

RESUMO

BACKGROUND: We assessed whether women who acquired HIV during tenofovir gel prophylaxis trials can be safely and effectively treated with tenofovir-containing antiretroviral therapy (ART). METHODS: Between May 2011 and October 2014, HIV seroconvertors from two tenofovir gel trials were recruited when eligible for ART (CD4+ T-cell count <350 cells/µl, pregnancy or AIDS-defining illness). Women were randomized to tenofovir-containing (tenofovir + lamivudine/emtricitabine + efavirenz) or tenofovir-sparing (zidovudine + lamivudine/emtricitabine + efavirenz) antiretroviral treatment regimens. The proportion with virological suppression, adverse events and drug switches were compared. RESULTS: Fifty-nine women were enrolled and followed-up for median 18 months (IQR 6-24). Twenty-nine women (7 tenofovir gel exposed, 22 tenofovir gel unexposed) were randomized to a tenofovir-containing and 30 (9 tenofovir gel exposed, 21 tenofovir gel unexposed) to a tenofovir-sparing regimen. Median baseline CD4+ T-cell count and viral load (VL) were 345 cells/µl (IQR 280-423) and 4.5 log copies/ml (sd 0.79), and did not differ by ART assignment. Overall VL suppression rates were 88.0% and 78.3% at 6 months (P=0.454) and 85.7% and 79.0% at 12 months (P=0.689) in women on the tenofovir-containing and tenofovir-sparing regimens, respectively. Toxicity-related drug switches were more frequent in women on the tenofovir-sparing than tenofovir-containing regimen (36.7% versus 0.0%, P<0.001). CONCLUSIONS: Preliminary data show that tenofovir-containing ART was effective and more tolerable in HIV seroconvertors from tenofovir gel prophylaxis trials and may be considered for use in women with prior tenofovir gel exposure. Clinical trials.gov NCT01387022.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Soropositividade para HIV/diagnóstico , HIV-1/efeitos dos fármacos , RNA Viral/genética , Tenofovir/uso terapêutico , Adulto , Alcinos , Terapia Antirretroviral de Alta Atividade , Benzoxazinas/uso terapêutico , Contagem de Linfócito CD4 , Ciclopropanos , Emtricitabina/uso terapêutico , Feminino , Infecções por HIV/imunologia , Infecções por HIV/prevenção & controle , Infecções por HIV/virologia , Soropositividade para HIV/imunologia , Soropositividade para HIV/virologia , HIV-1/patogenicidade , HIV-1/fisiologia , Humanos , Lamivudina/uso terapêutico , Segurança do Paciente , Gravidez , Prevenção Primária/métodos , RNA Viral/antagonistas & inibidores , RNA Viral/metabolismo , África do Sul , Resultado do Tratamento , Cremes, Espumas e Géis Vaginais/administração & dosagem , Carga Viral/efeitos dos fármacos , Zidovudina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA